Cost-effectiveness analysis: measuring the value of generics

Imagine buying a bottle of medicine that works exactly like the brand-name version but costs a fraction of the price. That’s the promise of generic drugs. But here’s the twist: not all generics are priced equally, and sometimes, picking the wrong one can cost your healthcare system billions. This is where cost-effectiveness analysis (CEA) comes in-a tool that helps us measure whether these cheaper alternatives truly deliver value.

When I first heard about CEA, I thought it was just another buzzword from economists. But after digging into how it works, I realized it’s actually a game-changer for patients, insurers, and even policymakers. Let me walk you through why this matters-and what we’re getting wrong.

What Is Cost-Effectiveness Analysis?

Cost-effectiveness analysis (CEA) is a method used to compare the costs of different treatments against their health outcomes. Think of it as a scorecard: if Drug A saves more lives per dollar than Drug B, it wins. In the world of generics, CEA asks a simple question-does switching to a generic drug give us better bang for our buck?

The concept started gaining traction in the 1970s when health economics became a formal field. By the time the Hatch-Waxman Act passed in 1984, the U.S. had created a streamlined path for approving generics via the Abbreviated New Drug Application (ANDA). Suddenly, companies could bring low-cost versions of patented drugs to market without redoing expensive clinical trials.

But here’s the catch: just because a drug is generic doesn’t mean it’s automatically cost-effective. Some generics still carry hefty price tags due to limited competition or complex manufacturing processes. That’s where CEA steps in-to separate the real deals from the overpriced imposters.

How Generics Save Money (and Where They Don’t)

Let’s talk numbers. According to the FDA, the entry of the first generic competitor typically slashes prices by 39% compared to the original brand-name drug. And once six or more generics hit the market? Prices plummet by over 95%. No wonder generics account for 90% of prescriptions dispensed in the U.S.-yet only make up 17% of total spending on prescription drugs.

• One generic: Average price drops by 39%
• Two generics: Prices fall by 54%
• Four generics: Prices drop by 79%
• Six+ generics: Prices crash below 5% of the original brand price

These savings add up fast. Between 2007 and 2017 alone, generics saved the U.S. healthcare system $1.7 trillion. That’s money that could’ve gone toward new treatments, hospital upgrades, or lowering out-of-pocket costs for patients.

So why aren’t all generics cheap? The answer lies in something called therapeutic substitution opportunities-even within the generic segment, some products cost way more than others for no good reason.

Therapeutic Substitution: Hidden Savings in Plain Sight

A 2022 study published in JAMA Network Open found that replacing high-cost generics with lower-cost alternatives of equivalent clinical value could cut spending by nearly 90%. Out of the top 1,000 most prescribed generics, researchers identified 45 “high-cost” options that had much cheaper substitutes doing the exact same job.

This means that simply swapping one generic for another-without changing the active ingredient-can lead to massive savings. Yet many payers don’t do this. Why? Because Pharmacy Benefit Managers (PBMs) often profit from spread pricing-the difference between what they charge insurers and what pharmacies actually pay. So even though a cheaper option exists, PBMs might keep pushing pricier generics because it benefits them financially.

The Problem With Current CEAs

If CEA is so powerful, why isn’t everyone using it correctly? Here’s the thing: most published studies fail to account for future generic pricing. In fact, a presentation at ISPOR 2021 revealed that 94% of cost-effectiveness analyses ignored expected price reductions after patent expiration.

That’s like buying a car today without considering its resale value five years down the road. If you know a rival model will come out next year, you’d adjust your expectations accordingly. Same goes for drugs-if a blockbuster medication loses patent protection soon, its price will likely tank. Ignoring that skews the entire analysis.

Dr. John Garrison put it bluntly in 2023: failing to factor in patent cliffs creates "pricing anomalies" that distort incentives for research and development. He argued that conventional CEA should include long-run marginal costs-not just current manufacturing expenses-but also R&D investments recouped during monopoly periods.

Real-World Examples of Smart CEA Use

In Europe, Health Technology Assessment (HTA) agencies routinely use CEA to decide which drugs get covered under national health systems. Over 90% of major European HTA bodies incorporate formal CEA into coverage decisions. Meanwhile, commercial insurers in the U.S. lag behind-with only 35% regularly applying rigorous CEA methods according to a 2022 AMCP survey.

Take insulin, for example. When biosimilar insulins entered the market, traditional CEA showed minimal benefit since both types controlled blood sugar similarly. But when analysts modeled long-term effects-including reduced hypoglycemia events and fewer emergency room visits-they discovered biosimilars were far more cost-effective. As a result, several Medicare Advantage plans switched formularies, saving millions annually.

Another case involves statins. Atorvastatin (Lipitor) dominated the market until patents expired and multiple generics flooded in. Early CEAs focused solely on cholesterol-lowering ability. Later models included cardiovascular event prevention rates, showing that combining certain generics yielded superior outcomes at lower costs.

Building Better Models: What Needs to Change

To improve CEA for generics, experts suggest three key changes:

1. Incorporate dynamic pricing forecasts: Instead of static snapshots, build models that reflect anticipated price drops post-patent expiry.
2. Include non-drug costs: Factor in monitoring, side effect management, and adherence issues tied to each treatment option.
3. Standardize data sources: Use consistent metrics like Federal Supply Schedule (FSS), Veterans Affairs (VA) pricing, or Average Wholesale Price (AWP)-with adjustments based on whether the drug is branded or generic.

The VA Health Economics Resource Center recommends specific multipliers: apply 121% FSS, 152% VA, or 64% AWP for brands; use 27% AWP for generics. These tweaks help level the playing field when comparing apples to oranges.

Additionally, training programs need expansion. Proper CEA requires knowledge spanning health economics, patent law, and pharma market dynamics. Most professionals spend 6-12 months mastering these skills before feeling confident running full-scale assessments.

Policy Shifts Driving Innovation

Recent legislation has amplified pressure to adopt smarter CEA practices. The Inflation Reduction Act (IRA) introduced provisions affecting Medicare Part D, including mandatory discounts on high-cost medications and expanded access to low-cost generics. Coupled with the Drug Pricing Reduction Act of 2020, these laws push payers to rethink formularies and prioritize true cost-effectiveness.

Meanwhile, NIH frameworks now emphasize multi-comparator evaluations acknowledging that competitor technologies may enter markets after initial assessments. Their guidance notes that "generic and biosimilar versions of comparators become available," requiring ongoing updates to existing models.

Looking ahead, expect increased sophistication in CEA methodologies. With over 300 small-molecule drugs losing patent protection between 2020-2025, accurate modeling of generic pricing dynamics will grow increasingly vital. Manufacturers themselves are adapting-setting prices strategically to stay just below established cost-effectiveness thresholds.